Serum biomarkers for personalization of nanotherapeutics-based therapy in different tumor and organ microenvironments
- 1 April 2014
- journal article
- research article
- Published by Elsevier in Cancer Letters
- Vol. 345 (1) , 48-55
Abstract
No abstract availableKeywords
This publication has 37 references indexed in Scilit:
- What does physics have to do with cancer?Nature Reviews Cancer, 2011
- Nitric Oxide-Mediated Tumoricidal Activity of Murine Microglial CellsTranslational Oncology, 2010
- Nanoparticle therapeutics: an emerging treatment modality for cancerNature Reviews Drug Discovery, 2008
- Beyond drug deliveryNature Nanotechnology, 2008
- Gelatinases mediate neutrophil recruitment in vivo: evidence for stimulus specificity and a critical role in collagen IV remodelingJournal of Leukocyte Biology, 2008
- Beneficial and detrimental influences of tissue inhibitor of metalloproteinase-1 (TIMP-1) in tumor progressionBiochimie, 2005
- Reduced cardiotoxicity and comparable efficacy in a phase IIItrial of pegylated liposomal doxorubicin HCl(CAELYX™/Doxil®) versus conventional doxorubicin forfirst-line treatment of metastatic breast cancerAnnals of Oncology, 2004
- Recurrent Epithelial Ovarian Carcinoma: A Randomized Phase III Study of Pegylated Liposomal Doxorubicin Versus TopotecanJournal of Clinical Oncology, 2001
- Pegylated-liposomal doxorubicin versus doxorubicin, bleomycin, and vincristine in the treatment of AIDS-related Kaposi's sarcoma: results of a randomized phase III clinical trial.Journal of Clinical Oncology, 1998
- Tumour uptake of doxorubicin in polyethylene glycol-coated liposomes and therapeutic effect against a xenografted human pancreatic carcinomaBritish Journal of Cancer, 1997